Pharmacoeconomic considerations in treating actinic keratosis

PharmacoEconomics

Volumn 27, Issue 6, 2009, Pages 451-464

  Neidecker, Marjorie V ^a   Davis Ajami, Mary Lynn ^a   Balkrishnan, Rajesh ^a   Feldman, Steven R ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; SUNSCREEN;

ACTINIC KERATOSIS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; CRYOTHERAPY; DRUG COST; EXCISION; HEALTH CARE COST; HUMAN; MEDICAL CARE; MEDICARE; MORBIDITY; PATIENT SATISFACTION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HUMANS; KERATOSIS, ACTINIC;

EID: 68349094926     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/00019053-200927060-00002     Document Type: Review

References (48)

1. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000 Jan; 42 (1 Pt 2): 8-10
2. National Center for Health Statistics. National Ambulatory Health Care Survey (NAMCS), public use data files: 2008 [online]. Available from URL: ftp://ftp.cdc.gov/pub/Health- Statistics/NCHS/Datasets/NAMCS/ [Accessed 2008Aug 15]
3. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994 Oct; 131 (4): 455-464
4. Marks R, Ponsford MW, Selwood TS, et al. Non-melanotic skin cancer and solar keratoses in Victoria. Med J Aust 1983 Dec 10-24; 2 (12): 619-622 (Pubitemid 14197506)
5. Green A, Beardmore G, Hart V, et al. Skin cancer in a Queensland population. J Am Acad Dermatol 1988 Dec; 19 (6): 1045-1052
6. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol 2000 Aug; 115 (2): 273-277 (Pubitemid 30637198)
7. Karagas MR, Zens MS, Nelson HH, et al. Measures of cumulative exposure from a standardized sun exposure history questionnaire: a comparison with histologic assessment of solar skin damage. Am J Epidemiol 2007 Mar 15; 165 (6): 719-726
8. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988 Apr 9; 1 (8589): 795-797 (Pubitemid 18094914)
9. Dodson JM, DeSpain J, Hewett JE, et al. Malignant potential of actinic keratoses and the controversy over treatment: a patient-oriented perspective. Arch Dermatol 1991;127 (7): 1029-1031
10. Chen GJ, Feldman SR, Williford PM, et al. Clinical diagnosis of actinic keratosis identifies an elderly population at high risk of developing skin cancer. Dermatol Surg 2005 Jan; 31 (1): 43-47
11. Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003 Mar; 48 (3): 425-429
12. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002 Apr; 146 Suppl. 61: 1-6
13. Green A. Changing patterns in incidence of non-melanoma skin cancer. Epithelial Cell Biol 1992 Jan; 1 (1): 47-51
14. Roberts WE. Dermatologic problems of older women. Dermatol Clin 2006 Apr; 24 (2): 271-80, viii
15. de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. Br J Dermatol 2007 Feb; 156 (2): 222-230
16. Helfand M, Gorman AK, Mahon S, et al. Actinic keratoses: final report. Agency for Healthcare Research and Quality; 2001 May 19. Report No.: contract 290-97-10018, task order no.6 [online]. Available from URL: http://www.cms.hhs. gov/coverage/download/8b3-t3.pdf [Accessed 2009 Jun 28]
17. McIntyre WJ, Downs MR, Bedwell SA. Treatment options for actinic keratoses. Am Fam Physician 2007 Sep 1; 76 (5): 667-671
18. Gold MH. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J Drugs Dermatol 2008 Jan; 7 (1): 23-25
19. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000 Jan; 42 (1 Pt 2): 25-28
20. Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006 Nov-Dec; 16 (6): 599-606
21. Agency for Healthcare Research and Quality, 2008 [online]. Available from URL: http://www.ahrq.gov/ [Accessed 2008 Jul 8]
22. American Academy of Dermatology, 2008 [online]. Available from URL: http://www.aad.org/ [Accessed 2008 Jul 8]
23. Higashi MK, Veenstra DL, Langley PC. Health economic evaluation of non-melanoma skin cancer and actinic keratosis. Pharmacoeconomics 2004; 22 (2): 83-94 (Pubitemid 38241495)
24. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press, 2005
25. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996 Aug 3; 313 (7052): 275-283
26. Muston D, Downs A, Rives V. An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat 2009 Jan; 1: 1-10. Epub ahead of print
27. The Society for Investigative Dermatology and The American Academy of Dermatology Association. The burden of skin diseases: 2005. Falls Church (VA): The Lewin Group, 2005 [online]. Available from URL: http://www. lewin.com/content/publications/april2005skindisease.pdf [Accessed 2008 Aug 25]
28. Warino L, Tusa M, Camacho F, et al. Frequency and cost of actinic keratosis treatment. Dermatol Surg 2006 Aug; 32 (8): 1045-1049 (Pubitemid 44197455)
29. Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis 2002 Aug; 70 (2 Suppl.): 30-36
30. Streeton CL, Gospodarevskaya E, Harris AH. How are solar keratoses treated by general practitioners in Australia? Int J Dermatol 2006 Mar; 45 (3): 272-276
31. Caekelbergh K, Annemans L, Lambert J, et al. Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in themanagement of actinic keratosis and basal cell carcinoma. Br J Dermatol 2006 Oct; 155 (4): 784-790 (Pubitemid 44352560)
32. Annemans L, Caekelbergh K, Roelandts R, et al. Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma. Eur J Dermatol 2008 Sep-Oct; 18 (5): 539-546
33. de Roos KP, Beljaards RC. The Delphi panel in the economic evaluation of photodynamic therapy for actinic keratosis and basal cell carcinoma: poor results? Br J Dermatol 2007 Jun; 156 (6): 1393-1394
34. Caekelbergh K, Annemans L. Interest in interests in photodynamic therapy: reply from the authors [letter]. Br J Dermatol 2007 Jun; 156 (6): 1393 (Pubitemid 47029843)
35. Weston A, Fitzgerald P. Discrete choice experiment to derive willingness to pay for methyl aminolevulinate photodynamic therapy versus simple excision surgery in basal cell carcinoma. Pharmacoeconomics 2004; 22 (18): 1195-1208 (Pubitemid 40075721)
36. Braathen LR, Szeimies R-M, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007; 56 (1): 125-143 (Pubitemid 44969292)
37. Halpern AC, Hanson LJ. Awareness of, knowledge of and attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians. Int J Dermatol 2004 Sep; 43 (9): 638-642
38. American College of Physicians. Information on cost-effectiveness: an essential product of a national comparative effectiveness program. Ann Intern Med 2008 Jun 17; 148 (12): 956-961
39. Tunis SR. Why Medicare has not established criteria for coverage decisions. N Engl J Med 2004 May 20; 350 (21): 2196-2198
40. Ginsburg ME. Cost-effectiveness: will the public buy it or balk? Health Aff (Millwood) 2004 Jan-Jun; Suppl. Web Exclusives: W4-297-299
41. Ulrich C, Hackethal M, Ulrich M, et al. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases. Br J Dermatol 2007 May; 156 Suppl. 3: 40-42 (Pubitemid 46632515)
42. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003 Apr 24; 348 (17): 1681-1691
43. Ulrich C, Schmook T, Nindl I, et al. Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. Br J Dermatol 2003 Nov; 149 Suppl. 66: 40-42 (Pubitemid 38064516)
44. Palm MD, O'Donoghue MN. Update on photoprotection. Dermatol Ther 2007 Sep-Oct; 20 (5): 360-376
45. Heckman CJ, Coups EJ, Manne SL. Prevalence and correlates of indoor tanning among US adults. J Am Acad Dermatol 2008 May; 58 (5): 769-780
46. Moyal DD, Fourtanier AM. Broad-spectrum sunscreens provide better protection from solar ultraviolet-simulated radiation and natural sunlight-induced immunosuppression in human beings. J Am Acad Dermatol 2008 May; 58 (5 Suppl. 2): S149-54
47. Lim HW, Cooper K. The health impact of solar radiation and prevention strategies: report of the Environment Council, American Academy of Dermatology. J Am Acad Dermatol 1999 Jul; 41 (1): 81-99 (Pubitemid 29336859)
48. Mettlin CJ. Skin cancer and ozone depletion: the case for global action. J Surg Oncol 2001 Jun; 77 (2): 76-78